Compare Enact Holdings Inc (ACT) vs Adaptive Biotechnologies Corp (ADPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enact Holdings Inc vs Adaptive Biotechnologies Corp — how do they compare? Enact Holdings Inc trades at $49.42 (market cap $6.75B), while Adaptive Biotechnologies Corp trades at $25.15 (market cap $4.04B). The key difference: Enact Holdings Inc is the larger of the two by market cap, and Enact Holdings Inc pays a 1.95% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ACT | ADPT | |
|---|---|---|
Market Cap | $6.75B | $4.04B |
Sector | Technology | Health |
52-Week High | $49.12 | $25.45 |
52-Week Low | $34.93 | $12.30 |
Enterprise Value | $7.05B | $4.10B |
Dividend Yield | 1.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →
